TRADE ALERT: Lock in some profits on Apellis
- Dylan Jovine
- Wednesday, April 26, 2023
I recommend selling half your shares in Apellis Pharmaceuticals, Inc (SYM: APLS)
March 2023 Issue: Schrodinger (SYM: SDGR)
- Dylan Jovine
- Thursday, March 16, 2023
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it.
UPDATE: Apellis Pharma (APLS) is still a “BUY”
- Dylan Jovine
- Tuesday, February 28, 2023
A lot of folks have written in to ask if we think Apellis Pharmaceuticals (SYM: APLS) is a still buy. We recommended shares at $48.42 on January 13, and watched it explode to a high of $70.75, or, 46% in less than two months. Shares are now at $65, after the market sell-off.
January 2023 Issue: Apellis Pharmaceuticals (SYM: APLS)
- Dylan Jovine
- Friday, January 13, 2023
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
TRADE ALERT: Lock in some profits on Apellis
- Dylan Jovine
- Wednesday, April 26, 2023
I recommend selling half your shares in Apellis Pharmaceuticals, Inc (SYM: APLS)
March 2023 Issue: Schrodinger (SYM: SDGR)
- Dylan Jovine
- Thursday, March 16, 2023
A.I. has started to revolutionize drug discovery. You see, right now there are a about 6,000 genetic diseases known to mankind – Liver Disease…Diabetes…Skin Cancer...Heart Disease… You name it.
UPDATE: Apellis Pharma (APLS) is still a “BUY”
- Dylan Jovine
- Tuesday, February 28, 2023
A lot of folks have written in to ask if we think Apellis Pharmaceuticals (SYM: APLS) is a still buy. We recommended shares at $48.42 on January 13, and watched it explode to a high of $70.75, or, 46% in less than two months. Shares are now at $65, after the market sell-off.
January 2023 Issue: Apellis Pharmaceuticals (SYM: APLS)
- Dylan Jovine
- Friday, January 13, 2023
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
Get FREE Weekly Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
